|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
00 |
deletion of a complete allele (I) |
- |
p.0 |
- |
RPS19_00022 |
- |
Large deletion; haploinsufficiency |
- |
Reduces RPS19 mRNA levels |
Decreased to 50% of controls (lymphoblastoid cell lines, BM CD34+) [1,2] |
- |
- |
18S rRNA processing defect, as indicated by increase in 21S pre-rRNA (increased 21S/18SE ratio). BM CD34- cells: ratio 3,3. BM CD34+ cells: ratio 1,7 [3] . Similar effects in yeast [4]. |
- |
- |
- |
[1] Chatr-Aryamontri et al (2004) Hum Mutat 24, 526-33; [2] Hamaguchi et al (2002) Blood 100, 2724-31; [3] Flygare et al (2007) Blood 109, 980-6; [4] Léger-Silvestre et al (2005) J Biol Chem 280, 38177-85 |
00 |
deletion of a complete allele (II) |
- |
p.0 |
- |
RPS19_00067 |
- |
Large deletion; haploinsufficiency |
- |
Reduces RPS19 mRNA levels |
Decreased to 50% of controls (lymphoblastoid cell lines, BM CD34+) [1,2] |
- |
- |
18S rRNA processing defect, as indicated by increase in 21S pre-rRNA (increased 21S/18SE ratio). BM CD34- cells: ratio 3,3. BM CD34+ cells: ratio 1,7 [3] . Similar effects in yeast [4]. |
- |
- |
- |
[1] Chatr-Aryamontri et al (2004) Hum Mutat 24, 526-33; [2] Hamaguchi et al (2002) Blood 100, 2724-31; [3] Flygare et al (2007) Blood 109, 980-6; [4] Léger-Silvestre et al (2005) J Biol Chem 280, 38177-85 |
00 |
deletion of a complete allele (III) |
- |
p.0 |
- |
RPS19_00069 |
- |
Large deletion; haploinsufficiency |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
00 |
deletion of a complete allele (IV) |
- |
p.0 |
- |
RPS19_00081 |
- |
Large deletion; haploinsufficiency |
- |
Reduces RPS19 mRNA levels |
RPS19 mRNA reduced |
Skewed SSU/LSU protein ratio |
- |
- |
- |
- |
- |
Badhai et al (2009) FEBS Lett 583(12), 2049-53 |
00 |
deletion of a complete allele (V) |
- |
p.0 |
- |
RPS19_00089 |
- |
Large deletion; haploinsufficiency |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
00 |
deletion of a complete allele (VI) |
- |
p.0 |
- |
RPS19_00094 |
- |
Large deletion; haploinsufficiency |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
00 |
t(1;19)(p32;q13) |
- |
p.0 |
- |
RPS19_00080 |
- |
Translocation |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
00 |
t(8;19)(q35;q13) |
- |
p.0 |
- |
RPS19_00079 |
- |
Translocation |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
00 |
t(X;19) (p21;q13) |
- |
p.0 |
- |
RPS19_00078 |
- |
Translocation; haploinsufficiency |
- |
Reduces RPS19 mRNA levels |
Normal in peripheral blood MNC, but reduced levels compared to controls in BM CD34+. No abnormal size transcript [1]. |
- |
- |
18S rRNA processing defect, as indicated by increase in 21S pre-rRNA (21S/18SE ratio: 3,1) (BM CD34+ cells) [2]. |
- |
- |
- |
[1] Hamaguchi et al (2002) Blood 100, 2724-31; [2] Flygare et al (2007) Blood 109, 980-6 |
02 |
c.1-2A>T (Reported 2 times) |
- |
p.0? |
- |
RPS19_00086 |
Intron 1 |
Acceptor splice site defect |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.1-1G>A |
- |
p.0 |
- |
RPS19_00065 |
Intron 1 |
Acceptor splice site defect |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.1-1G>C |
- |
p.0? |
- |
RPS19_00126 |
Intron 1 |
Acceptor splice site defect |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.1-1G>T |
- |
p.0 |
- |
RPS19_00064 |
Intron 1 |
Acceptor splice site defect |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.1A>G (Reported 5 times) |
- |
p.Met1Val |
- |
RPS19_00011 |
- |
Missense mutation |
transition |
Reduces RPS19 mRNA levels |
Reduced to 70-80% of controls in lymphoblastoid cell lines [1]. Part of the mutated mRNA could use a downstream in-frame AUG, the other is degraded through NMD. |
Skewed SSU/LSU protein ratio[2] |
- |
- |
- |
- |
- |
[1] Chatr-Aryamontri et al (2004) Hum Mutat 24, 526-33; [2]Badhai et al (2009) FEBS Lett 583(12), 2049-53 |
02 |
c.2T>A |
- |
p.Met? |
- |
RPS19_00095 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.3G>A (Reported 4 times) |
- |
p.Met1Ile |
- |
RPS19_00014 |
- |
Missense mutation |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.3G>C |
- |
p.Met1Ile |
- |
RPS19_00012 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.3G>T (Reported 5 times) |
- |
p.Met1Ile |
- |
RPS19_00013 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.10_13delGTTA |
- |
p.Val4LeufsX2 |
- |
RPS19_00091 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.13_14insA (Reported 2 times) |
- |
p.Thr5AsnfrX46 |
- |
RPS19_00037 |
- |
Insertion |
slippage |
Reduces RPS19 mRNA levels |
Decreased to 50-60% of controls due to NMD of the aberrant mRNA (lymphoblastoid cell lines) [1] |
- |
- |
- |
- |
- |
translation inhibition by cycloheximide stabilizes the mutant mRNA form, as expected in NMD and nonstop decay |
[1] Chatr-Aryamontri et al (2004) Hum Mutat 24, 526-33 |
02 |
c.14delC |
- |
p.Thr5MetfsX2 |
- |
RPS19_00096 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.20_32del |
- |
p.Lys7SerfsX18 |
- |
RPS19_00038 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.25_42del |
- |
p.Val9_Phe14del |
- |
RPS19_00039 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.28_29insT |
- |
p.Asn10IlefsX41 |
- |
RPS19_00114 |
- |
Insertion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.31C>T (Reported 5 times) |
- |
p.Gln11X |
- |
RPS19_00001 |
- |
Nonsense mutation |
transition |
Reduces RPS19 mRNA levels |
2 to 4-fold decreased compared to controls, likely subjected to NMD (BM CD34+ and peripheral blood MNC) [1] |
3-fold protein reduction in CD34+ BM cells, normal levels in peripheral MNC cells. Putative truncated protein not detectable [1] |
- |
- |
- |
- |
- |
[1] Gazda et al (2004) Br J Haematol 127, 105-13 |
02 |
c.34C>T (Reported 3 times) |
- |
p.Gln12X |
- |
RPS19_00002 |
- |
Nonsense mutation |
transition |
Unclassified |
Aberrant mRNA might undergo NMD |
- |
- |
Lower rate of ribosomal biogenesis in human dermal fibroblasts and defect in ITS1 processing of 18S rRNA (increase in 21S to 18SE pre-rRNA ratio). Accumulation of 45S and 41S precursors. Dermal fibroblasts show rounded and condensed nucleoli, with changes in nucleolar organization [1] |
- |
Impairs growth of skin fibroblasts [1] |
- |
[1]Choesmel et al (2007) Blood 109, 1275-83 |
02 |
c.34_47del |
- |
p.Gln12SerfsX34 |
- |
RPS19_00115 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.36_37insAG |
- |
p.Glu13ArgfsX17 |
- |
RPS19_00040 |
- |
Insertion |
slippage |
Reduces RPS19 mRNA levels |
2 to 4-fold decreased compared to controls. Aberrant mRNA not detectable, likely subjected to NMD (BM CD34+ and peripheral blood MNC) [1] |
- |
- |
- |
- |
- |
- |
[1] Gazda et al (2004) Br J Haematol 127, 105-13 |
02 |
c.43G>T (Reported 2 times) |
- |
p.Val15Phe |
- |
RPS19_00015 |
- |
Missense mutation |
transversion |
Reduces RPS19 protein levels and impairs nucleolar localization |
- |
Reduced protein levels. Protein instability (in Cos7 and HEK293 cells) [1,2] |
No nucleolar localization, no ribosome association(in Cos7 and HEK293 cells) [1,2] |
The yeast orthologue mutation (p.Ile15Phe) causes 18S rRNA processing defect, as indicated by increase of 21S rRNA and nucleolar accumulation of pre-40S particles [3] |
- |
The yeast orthologue mutation (p.Ile15Phe) abolishes the ability of Rps19A protein to support cell growth [3] |
- |
[1] Angelini et al (2007) Hum Mol Genet 16, 1720-7; [2] Da Costa et al (2003) Blood 101, 5039-45; [3] Léger-Silvestre et al (2005) J Biol Chem 280, 38177-85 |
02 |
c.49G>C |
- |
p.Ala17Pro |
- |
RPS19_00098 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.53T>C |
- |
p.Leu18Pro |
- |
RPS19_00016 |
- |
Missense mutation |
transition |
Reduces RPS19 protein levels and impairs nucleolar localization |
- |
Reduced protein levels. Protein instability (in HEK293 cells) [1] |
No nucleolar localization, no ribosome association(in Hela and HEK293 cells) [1] |
- |
- |
- |
- |
[1] Angelini et al (2007) Hum Mol Genet 16, 1720-7 |
02 |
c.53T>G |
- |
p.Leu18Arg |
- |
RPS19_00017 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.53_54insAGA |
- |
p.Leu18_Ala19insGlu |
- |
RPS19_00041 |
- |
Insertion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.58delG |
- |
p.Ala20ProfsX9 |
- |
RPS19_00042 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.58G>C |
- |
p.Ala20Pro |
- |
RPS19_00112 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.62T>C |
- |
p.Phe21Ser |
- |
RPS19_00018 |
- |
Missense mutation |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.71+1G>A (Reported 2 times) |
- |
p.0 |
- |
RPS19_00066 |
Intron 2 |
Donor splice site defect |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.71+1G>C |
- |
p.0? |
- |
RPS19_00097 |
Intron 2 |
Donor splice site defect |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
02 |
c.71+3_71+6delGAGT |
- |
p.0 |
- |
RPS19_00068 |
Intron 2 |
Donor splice site defect |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
LOH 3' to exon 3 |
- |
p.0 |
- |
RPS19_00083 |
- |
Intragenic deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.72-2A>C |
- |
p? |
- |
RPS19_00099 |
Intron 2 |
Acceptor splice site defect |
transversion |
Reduces RPS19 mRNA levels |
Reduces RPS19 mRNA levels |
Reduces protein levels |
- |
Yes |
- |
G1 arrest |
- |
Badhai et al (2009) Biochim Biophys Acta 1792(10), 1036-42 |
03 |
c.72-1G>A |
- |
p.0? |
- |
RPS19_00116 |
Intron 2 |
Acceptor splice site defect |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.83T>G |
- |
p.Leu28Arg |
- |
RPS19_00103 |
- |
Missense mutation |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.88delG |
- |
p.Val30SerfsX46 |
- |
RPS19_00117 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.93delC |
- |
p.Glu32AsnfsX44 |
- |
RPS19_00100 |
- |
Deletion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.98G>A (Reported 2 times) |
- |
p.Trp33X |
- |
RPS19_00003 |
- |
Nonsense mutation |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.103dupG |
- |
p.Asp35GlyfsX16 |
- |
RPS19_00102 |
- |
Insertion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.104_105insA (Reported 2 times) |
- |
p.Asp35GlufsX16 |
- |
RPS19_00043 |
- |
Insertion |
slippage |
Reduces RPS19 mRNA levels |
RPS19 mRNA reduced |
Skewed SSU/LSU protein ratio |
- |
- |
- |
- |
- |
Badhai et al (2009) FEBS Lett 583(12), 2049-53 |
03 |
c.106_107insA (Reported 2 times) |
- |
p.Thr36AsnfsX15 |
- |
RPS19_00044 |
- |
Insertion |
slippage |
Reduces RPS19 mRNA levels |
2 to 4-fold decreased compared to controls; low amount of aberrant mRNA detectable, likely subjected to NMD (BM CD34+ and peripheral blood MNC) [1] |
2-fold protein reduction in CD34+ BM cells, normal levels in peripheral MNC cells. Putative truncated protein not detectable [1] |
- |
- |
- |
- |
- |
[1] Gazda et al (2004) Br J Haematol 127, 105-13 |
03 |
c.112A>T |
- |
p.Lys38X |
- |
RPS19_00090 |
- |
Nonsense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.[134_135delinsAA;139_140insTC] |
- |
p.[Leu45Gln;Pro47LeufsX30] |
- |
RPS19_00045 |
- |
Insertion/Deletion |
- |
Unclassified |
Levels similar to controls could exclude NMD (BM CD34+ and PB MNC) [1] |
- |
- |
18S rRNA processing defect, as indicated by increase in 21S pre-rRNA (21S/18SE ratio:3,8) (BM CD34- cells) [2] |
- |
- |
- |
[1] Hamaguchi et al (2002) Blood 100, 2724-31; [2] Flygare et al (2007) Blood 109, 980-6 |
03 |
c.140C>T (Reported 2 times) |
- |
p.Pro47Leu |
- |
RPS19_00019 |
- |
Missense mutation |
transition |
Impairs ribosomal association but not nucleolar localization |
- |
Apparently normal protein levels. Intermediate stability (HEK293) [1,2] |
Nucleolar localization, but no ribosome association(HeLa-HEK293) [1] |
No alteration in polysomal profile. 18S rRNA processing defect, as indicated by increased ratio of 21S to 18SE pre-rRNA (lymphoblastoid cell lines) [2] |
- |
- |
21S/18SE ratio was not reported for this single mutation, but for 6 DBA lymphoblastoid cell lines with 3 different RPS19 mutations (mean value DBA: 1,22-/-0,39; controls: 0,68+/-0,1) [2] |
[1] Angelini et al (2007) Hum Mol Genet 16, 1720-7; [2] Idol et al (2007) Blood Cells Mol Dis 39, 35-43 |
03 |
c.144C>A |
- |
p.Tyr48X |
- |
RPS19_00004 |
- |
Nonsense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.154T>C (Reported 2 times) |
- |
p.Trp52Arg |
- |
RPS19_00020 |
- |
Missense mutation |
transition |
Impairs ribosomal association but not nucleolar localization |
- |
Apparently normal protein levels. Intermediate stability (HEK293) [1] |
Nucleolar localization, but no ribosome association(HeLa-HEK293) [1] |
- |
- |
- |
- |
[1] Angelini et al (2007) Hum Mol Genet 16, 1720-7 |
03 |
c.155G>A |
- |
p.Trp52X |
- |
RPS19_00005 |
- |
Nonsense mutation |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.156G>A |
- |
p.Trp52X |
- |
RPS19_00125 |
- |
Nonsense mutation |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.156G>C |
- |
p.Trp52Cys |
- |
RPS19_00021 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.166C>T (Reported 4 times) |
- |
p.Arg56X |
- |
RPS19_00006 |
- |
Nonsense mutation |
CpG |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.167G>A (Reported 9 times) |
- |
p.Arg56Gln |
- |
RPS19_00023 |
- |
Missense mutation; Leucine not effective in increasing translational efficiency in lymphocytes. |
CpG |
Impairs ribosomal association but not nucleolar localization |
- |
Apparently normal protein levels. Intermediate stability (Cos7-HEK293) [1,2] |
Nucleolar localization, but no ribosome association(Cos7-HeLa-HEK293) [1,2] |
- |
Translation rate reduced to 63% of controls after transfection in K562 cells [3]. In lymphocytes, translation is reduced to 55% of controls both in basal conditions and after PHA activation [3] |
- |
translation was found reduced in lymphocytes from all the DBA subjects studied irrespective of the presence of RPS19 mutations [3] |
[1] Angelini et al (2007) Hum Mol Genet 16, 1720-7; [2] Da Costa et al (2003) Blood 101, 5039-45; [3] Cmejlova et al (2006) Haematologica 91, 1456-64 |
03 |
c.169G>C |
- |
p.Ala57Pro |
- |
RPS19_00024 |
- |
Missense mutation |
transversion |
Reduces RPS19 protein levels and impairs nucleolar localization |
- |
Reduced protein levels. Protein instability (in HEK293 cells) [1] |
No nucleolar localization, no ribosome association(in Hela and HEK293 cells) [1] |
- |
- |
- |
- |
[1] Angelini et al (2007) Hum Mol Genet 16, 1720-7 |
03 |
c.172G>C |
- |
p.Ala58Pro |
- |
RPS19_00101 |
- |
Missense mutation |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.172+1G>C |
- |
p.0? |
- |
RPS19_00104 |
Intron 3 |
Donor splice site defect |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
03 |
c.172+1G>T (Reported 2 times) |
- |
p.0? |
- |
RPS19_00087 |
Intron 3 |
Donor splice site defect |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
LOH 5' to exon 4 |
- |
p.0 |
- |
RPS19_00084 |
- |
Intragenic deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.173-7_174del |
- |
p.0? |
- |
RPS19_00118 |
Intron 3/Exon 4 |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.173-2A>G |
- |
p.0? |
- |
RPS19_00105 |
Intron 3 |
Acceptor splice site defect |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.173-2A>T |
- |
p.Ala58_Thr60del |
- |
RPS19_00070 |
Intron 3 |
Acceptor splice site defect |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.173-1delG |
- |
p.Ala58_Thr60del |
- |
RPS19_00071 |
Intron 3 |
Acceptor splice site defect |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.173-1G>A |
- |
p.Ala58_Thr60del |
- |
RPS19_00072 |
Intron 3 |
Acceptor splice site defect |
transition |
Unclassified |
Normal mRNA levels (peripheral blood MNC) [1] |
- |
- |
- |
- |
- |
- |
[1] Gazda et al (2004) Br J Haematol 127, 105-13 |
04 |
c.176C>T |
- |
p.Ser59Phe |
- |
RPS19_00025 |
- |
Missense mutation |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.178A>C |
- |
p.Thr60Pro |
- |
RPS19_00092 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.182C>A |
- |
p.Ala61Glu |
- |
RPS19_00026 |
- |
Missense mutation; the pathogenic role for this mutation was questioned by some authors [Léger-Silvestre et al (2005) J Biol Chem 280, 38177-85] |
transversion |
Reduces RPS19 protein levels and impairs nucleolar localization |
- |
Reduced protein levels. Protein instability (in HEK293 cells) [1] |
No nucleolar localization, no ribosome association(in Hela and HEK293 cells) [1] |
The yeast orthologue mutation (p.Ala62Ser) does not influence 21S/18S ratio [2] |
- |
The yeast orthologue mutation (p.Ala62Ser) does not influence the ability of Rps19A protein to support cell growth [2] |
- |
[1] Angelini et al (2007) Hum Mol Genet 16, 1720-7; [2] Léger-Silvestre et al (2005) J Biol Chem 280, 38177-85 |
04 |
c.184C>T (Reported 13 times) |
- |
p.Arg62Trp |
- |
RPS19_00027 |
- |
Missense mutation |
CpG |
Impairs ribosomal association but not nucleolar localization |
Normal mRNA levels (BM CD34+ and peripheral blood MNC) [1] |
Apparently normal protein levels [2,3]. Intermediate stability and increased degradation, partly mediated by proteasome (Cos7-HEK293) [2] |
Nucleolar localization, but no ribosome association(Cos7-HeLa-HEK293) [2,3] |
The yeast orthologue mutation (R63Q) causes 18S rRNA processing defect, as indicated by increase in 21S rRNA and nucleolar accumulation of pre-40S particles [4] |
- |
The yeast orthologue mutation (p.Arg63Gln) impairs cell growth in yeast [4] |
- |
[1] Hamaguchi et al (2002) Blood 100, 2724-31; [2] Angelini et al (2007) Hum Mol Genet 16, 1720-7; [3] Da Costa et al (2003) Blood 101, 5039-45; [4] Léger-Silvestre et al (2005) J Biol Chem 280, 38177-85 |
04 |
c.185G>A (Reported 9 times) |
- |
p.Arg62Gln |
- |
RPS19_00028 |
- |
Missense mutation; Leucine not effective in increasing translational efficiency in lymphocytes. |
CpG |
Impairs ribosomal association but not nucleolar localization |
- |
Apparently normal protein levels. Intermediate stability (HEK293) [1] |
Nucleolar localization, but no ribosome association (HeLa-HEK293) [1]. It alters the ultrastructural nucleolar organization in dermal fibroblasts [2] |
18S rRNA processing defect both in yeast (orthologue mutation: p.Arg63Gln) and in human dermal fibroblasts, as indicated by increase in 21S pre-rRNA [2,3]. Accumulation of 45S and 41S precursors is observed in dermal fibroblasts [2]; yeast cells show nucleolar accumulation of pre-40S particles [3] |
Translation rate reduced to 56% of controls after transfection in K562 cells [4]. In lymphocytes, translation is reduced to 66% of controls in basal conditions and to 62% after PHA activation [4] |
The human mutation impairs growth of skin fibroblasts [2] and the yeast orthologue mutation (p.Arg63Gln) impairs but does not abolish cell growth in yeast [3] |
translation was found reduced in lymphocytes from all the DBA subjects studied irrespective of the presence of RPS19 mutations [4] |
[1] Angelini et al (2007) Hum Mol Genet 16, 1720-7; [2]Choesmel et al (2007) Blood 109, 1275-83; [3] Léger-Silvestre et al (2005) J Biol Chem 280, 38177-85; [4] Cmejlova et al (2006) Haematologica 91, 1456-64 |
04 |
c.187_189insCAC |
- |
p.His63dup |
- |
RPS19_00119 |
- |
Insertion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.191T>C |
- |
p.Leu64Pro |
- |
RPS19_00029 |
- |
Missense mutation |
transition |
Unclassified |
- |
- |
- |
The yeast orthologue mutation (p.Ile65Pro) causes 18S rRNA processing defect, as indicated by increase in 21S rRNA and nucleolar accumulation of pre-40S particles [1] |
- |
The yeast orthologue mutation (p.Ile65Pro) abolishes the ability of Rps19A protein to support cell growth [1] |
- |
[1] Léger-Silvestre et al (2005) J Biol Chem 280, 38177-85 |
04 |
c.195C>G (Reported 2 times) |
- |
p.Tyr65X |
- |
RPS19_00111 |
- |
Nonsense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.197_207del |
- |
p.Leu66ArgfsX84 |
- |
RPS19_00046 |
- |
Deletion; Leucine not effective in increasing translational efficiency in lymphocytes. |
- |
Reduces RPS19 protein levels and impairs nucleolar localization |
- |
Protein instability [1] |
No nucleolar localization [1] |
- |
Cellular translation rate is not affected in K562 cells, but translation is reduced in patient\\\'s lymphocytes (basal translation: 60% , activated translation: 50%) [1] |
- |
translation was found reduced in lymphocytes from all the DBA subjects studied irrespective of the presence of RPS19 mutations [1] |
[1] Cmejlova et al (2006) Haematologica 91, 1456-64 |
04 |
c.203_204insG |
- |
p.Gly69TrpfsX85 |
- |
RPS19_00109 |
- |
Insertion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.212G>A |
- |
p.Gly71Glu |
- |
RPS19_00120 |
- |
Missense mutation |
transition |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.222delC |
- |
p.Met75X |
- |
RPS19_00047 |
- |
Nonsense mutation |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.226A>C |
- |
p.Thr76Pro |
- |
RPS19_00030 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.233_250del |
- |
p.Ile78_Gln83del |
- |
RPS19_00048 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.242_243insG |
- |
p.Arg82ThrfsX72 |
- |
RPS19_00049 |
- |
Insertion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.250_251delAG |
- |
p.Arg84LysfsX69 |
- |
RPS19_00050 |
- |
Deletion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.250_251insA |
- |
p.Arg84LysfsX70 |
- |
RPS19_00051 |
- |
Insertion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.274_304del |
- |
p.Phe92GlyfsX9 |
- |
RPS19_00052 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.280C>T (Reported 10 times) |
- |
p.Arg94X |
- |
RPS19_00007 |
- |
Nonsense mutation |
CpG |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.281G>T |
- |
p.Arg94Leu |
- |
RPS19_00088 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.284delG |
- |
p.Gly95AlafsX16 |
- |
RPS19_00121 |
- |
Deletion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.289_290insAGGC |
- |
p.Lys97ArgfsX58 |
- |
RPS19_00122 |
- |
Insertion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.295_296delGT |
- |
p.Val99GlyfsX54 |
- |
RPS19_00053 |
- |
Deletion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.296_297delTG |
- |
p.Val99GlyfsX54 |
- |
RPS19_00123 |
- |
Deletion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.301C>T |
- |
p.Arg101Cys |
- |
RPS19_00124 |
- |
Missense mutation |
CpG |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.302G>A (Reported 7 times) |
- |
p.Arg101His |
- |
RPS19_00031 |
- |
Missense mutation |
CpG |
Impairs ribosomal association but not nucleolar localization |
Normal mRNA levels (peripheral blood MNC) [1] |
Apparently normal protein levels. Intermediate stability and increased degradation, partly mediated by proteasome (HEK293) [2] |
Nucleolar localization, but no ribosome association (HeLa-HEK293) [2]. |
- |
- |
- |
- |
[1] Gazda et al (2004) Br J Haematol 127, 105-13; [2] Angelini et al (2007) Hum Mol Genet 16, 1720-7 |
04 |
c.305G>C |
- |
p.Arg102Pro |
- |
RPS19_00106 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.307delG |
- |
p.Val103SerfsX8 |
- |
RPS19_00054 |
- |
Deletion |
slippage |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.320T>G |
- |
p.Leu107Arg |
- |
RPS19_00107 |
- |
Missense mutation |
transversion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.328delC |
- |
p.Leu110X |
- |
RPS19_00055 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
04 |
c.338_340delTGG |
- |
p.Val113del |
- |
RPS19_00143 |
- |
Deletion |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Aspesi et al (2018) Hum Mutat in press |